Drug intelligence / Profile preview

YST-162

Development stage: Phase 1
Lead developer: Yangshengtang
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**YST-162** is a novel neutralizing monoclonal antibody developed by Yangshengtang Co., Ltd. for the treatment of chronic hepatitis B (CHB). It specifically targets the hepatitis B surface antigen (HBsAg), aiming to neutralize it and potentially reduce viral persistence and burden. The drug is in early clinical development, with Phase 1 trials evaluating safety, tolerability, and pharmacokinetics in healthy volunteers (YST-162-101) and CHB patients (YST-162-102), using single ascending doses up to 1200 mg administered intravenously.[4][5][7][16]

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on YST-162.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YST-162.

Explore the full profile